Back grey_arrow_rt.gif
 
Fatty Liver, NASH, NAFLD
 
NASH - Nonalcoholic steatohepatitis NAFLD -
nonalcoholic fatty liver disease
 
null.gif
 
 
  1. Fatty Liver in HIV - (07/18/17)
     
  2. Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease A Randomized Clinical Trial - NASH, hypertension, lipids, liver enzymes, weight loss - (10/20/17)
     
  3. Fatty Liver in HIV+ at IAS - (08/05/17)
     
  4. Fatty Liver / NASH at EASL - (07/03/17)
     
  5. IDWeek: Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy - (10/11/17)
     
  6. IDWeek: Faster Fatty Liver Progression With Statin Than Placebo in SATURN HIV Trial - Mark Mascolini (10/11/17)
     
  7. EASL: Serum Cholesterol Changes Associated with NGM282 Treatment in Obese Insulin Resistant Cynomolgus Monkeys and NASH Patients are Reversed with Lipid Lowering Agents - (04/24/17)
     
  8. EASL: NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients - (04/24/17)
     
  9. EASL: Efficacy and Safety of Simtuzumab for the Treatment of NASH with Bridging Fibrosis or Cirrhosis: Results of Two Phase 2b, Dose-Ranging, Randomized, Placebo-Controlled Trials - (05/23/17)
     
  10. Fatty Liver, NAFLD, NASH Definitions - (06/29/17)
     
    ------------
     
  11. The prevalence of NAFLD in Africa was estimated to be about 13% - The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD - (01/20/21)
     
  12. Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration - (01/14/21)
     
  13. AASLD: Efficacy and safety of subcutaneous semaglutide once-daily versus placebo in patients with nonalcoholic steatohepatitis
    Semaglutide Resolves NASH in Big Placebo-Controlled Trial
    - (01/07/21)
     
  14. AASLD: HIGH PREVALENCE OF FATTY LIVER DISEASE [FLD] AND ADVANCED FIBROSIS IN AN URBAN MULTIETHNIC US COHORT OF PERSONS WITH HIV - (12/21/20)
     
  15. AASLD: PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND FIBROSIS IN AMERICAN ADULTS: A POPULATION-BASED STUDY - (12/21/20)
     
  16. AASLD: GLOBAL PREVALENCE OF HEPATITIS C VIRUS IN WOMEN OF CHILDBEARING AGE IN 2019: A MODELING STUDY - (12/21/20)
     
  17. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/21/20)
     
  18. AdverseReactComor: Non-alcoholic fatty liver disease (NAFLD) in HIV-monoinfected patients: results from the European ECHAM study - (12/14/20)
     
  19. AASLD: NAFLD AND ALCOHOL-RELATED LIVER DISEASE ARE PRIMARY DRIVERS OF CURRENT AND FUTURE CAUSES OF CIRRHOSIS AMONG WOMEN IN NORTH AMERICA - (12/03/20)
     
  20. AASLD: SEMAGLUTIDE TREATMENT IN SUBJECTS WITH NAFLD: EFFECTS ASSESSED BY MAGNETIC RESONANCE ELASTOGRAPHY AND MAGNETIC RESONANCE IMAGING PROTON DENSITY FAT FRACTION - (12/02/20)
     
  21. AASLD: RESOLVE-IT Phase 3 of Elafibranor in NASH: Final Results of the Week 72 Interim Surrogate Efficacy Analysis - (12/02/20)
     
  22. AASLD: HCC, Decompensation, Alcohol, Tied to Death in Liver Patients With COVID-19 - Mark Mascolini (12/01/20)
     
  23. AASLD: Predictors Of Outcomes Of Covid-19 In Patients With Chronic Liver Disease: US Multi-center Study. - (12/01/20)
     
  24. AASLD: A 52-WEEK MULTI-CENTER DOUBLE-BLIND RANDOMIZED PHASE 2 STUDY OF SELADELPAR, A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPAR-DELTA) AGONIST, IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) - (12/01/20)
     
  25. AASLD: What Are the Current Treatment Options for our Patients with NAFLD/NASH ? - (12/01/20)
     
  26. AASLD: Patient-Reported Outcomes in Patients with Chronic Hepatitis C: Data from the Global Liver Registry - (12/01/20)
     
  27. AASLD: FIB -4 and FibroScan Can Identify Patients With Nonalcoholic Fatty Liver Disease Who Are at Risk of Liver-Related Events: Results of a Longitudinal Analysis With Comparison With Liver Biopsy - (12/01/20)
     
  28. AASLD: Identification of Undiagnosed NASH: Development and Application of a Real-world Prediction Model - (12/01/20)
     
  29. AASLD: ECONOMIC BURDEN OF NASH-ASSOCIATED CIRRHOSIS: US PAYOR'S PERSPECTIVE - (12/01/20)
     
  30. AASLD: Noninvasive Assessments to Identify Patients With Advanced Fibrosis Due to NASH: Screened Population From the REGENERATE Trial - (12/01/20)
     
  31. AASLD: Evaluation of Obeticholic Acid Efficacy in Patients With NASH Who Were Monitored Using Noninvasive Tests: A Post Hoc Analysis of the REGENERATE Trial - (12/01/20)
     
  32. AASLD: Prediction accuracy of the NASHmap algorithm designed to screen for presence of NASH - (12/01/20)
     
  33. AASLD: Prediction accuracy of the NASHmap algorithm designed to screen for presence of NASH - (12/01/20)
     
  34. AASLD: In 20-Year NAFLD Study, Lean Have Higher Death Rate Than Obese - Mark Mascolini (12/01/20)
     
  35. AASLD: Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study - (11/24/20)
     
  36. AASLD: Systematic Review and Meta-analysis of FIB-4 for the Diagnosis of Advanced Fibrosis due to Nonalcoholic Steatohepatitis - (11/24/20)
     
  37. AASLD: Final analysis of a 24-week, randomized, double blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - Mark Mascolini (11/24/20)
     
  38. AASLD: Novel, first-in-class, fatty acid synthase (FASN) inhibitor, TVB-2640 demonstrates clinically significant reduction in liver fat by MRI-PDFF, and ALT in NASH: a phase 2 randomized placebo controlled TRIAL (FASCINATE-1). - Mark Mascolini (11/24/20)
     
  39. AASLD: Safety and Drug-Drug Interaction of Tropifexor in Combination With Licogliflozin in Healthy but Overweight to Obese Subjects in Support of a Ph2b Combination Study ELIVATE - (11/24/20)
     
  40. AASLD: LIK066 (LICOGLIFLOZIN), AN SGLT1/2 INHIBITOR, IMPROVES MARKERS OF HEPATIC AND METABOLIC HEALTH IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: FULL STUDY ANALYSIS OF A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2A STUDY - (11/24/20)
     
  41. AASLD: Cilofexor and Firsocostat in Combination Lead to Greater Reductions in Serum Bile Acids, Which Are Associated With Treatment Response in Patients With Advanced Fibrosis Due to NASH - (11/24/20)
     
  42. AASLD: Combination Treatment With Cilofexor and Firsocostat Normalizes Cell Death Marker Cytokeratin 18 in Patients With Advanced Fibrosis Due to NASH - (11/24/20)
     
  43. AASLD: North America's Largest Meta-Analysis on the Prevalence of NAFLD, NASH, and Advanced Fibrosis (F3-F4) - (11/24/20)
     
  44. AASLD: Validation of a Machine Learning-Based Approach (DELTA Liver Fibrosis Score) for the Assessment of Histologic Response in Patients With Advanced Fibrosis Due to NASH - (11/24/20)
     
  45. AASLD: Clinical characteristics used for machine learning identification of fast progressors among patients with NASH - (11/24/20)
     
  46. AASLD: A phase 2, randomized, double-blind, placebo-controlled dose-finding study of the efficacy and safety of namodenoson (CF102), an A3 adenosine receptor (A3AR) agonist, in treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). - A3AR Agonist Improves NAFLD-Related Variables in Phase 2 Trial - (11/24/20)
     
  47. AASLD: Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study - (11/24/20)
     
  48. AASLD: Survival After Liver Transplant Similar With NASH and Other Causes - Mark Mascolini (11/24/20)
     
  49. AASLD: Obesity Plus High Liver Fat Boost Odds of Hospital Admission With Severe COVID-19 -Mark Mascolini (11/24/20)
     
  50. AASLD: Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)
     
  51. AASLD: Lipid Management in a 24-Week, Randomized, Double-Blind, Placebo-Controlled Study of Aldafermin (NGM282) - (11/23/20)
     
  52. AASLD: Aldafermin (NGM282) Produces Greater Anti-Fibrotic Response in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/23/20)
     
  53. AASLD: Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - (11/23/20)
     
  54. AASLD: Testosterone Helps Diet and Exercise Improve Sarcopenia in Men With Cirrhosis - Mark Mascolini (11/23/20)
     
  55. AASLD: Change in lipid markers throughout early adulthood is associated with prevalent NAFLD in mid-life: the coronary artery risk development in young adults (CARDIA) study - Mark Mascolini (11/23/20)
     
  56. AASLD: The microbiome changes induced by bariatric surgery protects against obesity and nonalcoholic fatty liver disease by decreasing gastric inhibitory protein and increasing hepatic NKT cell expression - Mark Mascolini (11/20/20)
     
  57. AASLD: A Random Forest Classifier Based on a 30-Gene Signature Distinguishes Patients With Bridging Fibrosis From Those With Cirrhosis Due to NASH (11/20/20)
     
  58. AASLD: Fc-FGF21 Fusion Protein Cuts Liver Fat, Improves Fibrosis in 4-Arm NASH Trial - Mark Mascolini (11/20/20)
     
  59. AASLD: Low Liver Fat Tied to Higher CHD Risk in Viscerally Obese People - Mark Mascolini (11/20/20)
     
  60. AASLD: Abnormal Liver Tests at COVID Hospitalization Tied to Severe Disease, Death - Mark Mascolini (11/18/20)
     
  61. AASLD: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)
     
  62. AASLD: Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)
     
  63. AASLD: The Lipidomics of HIV-related NAFLD - (11/17/20)
     
  64. AASLD: Treatment with Growth Hormone-Releasing Hormone Analog ReducesVEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)
     
  65. AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
     
  66. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis - (11/05/20)
     
  67. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study - (11/05/20)
     
  68. EASL: EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects - (09/28/20)
     
  69. EASL EDP-297, a novel and potent fxr agonist, exhibit robust anti- fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis - (09/28/20)
     
  70. EASL A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and in rodent models of liver injury and NASH - (09/28/20)
     
  71. EASL Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with nonalcoholic fatty liver disease A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors - (09/25/20)
     
  72. EASL Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with nonalcoholic fatty liver disease - (09/25/20)
     
  73. EASL Optimal Non-Invasive Screening Strategy for Nonalcoholic Fatty Liver Disease in a Prospective Cohort of Patients with Type 2 Diabetes - (09/25/20)
     
  74. EASL Associations Between Serum Bile-Acid Species With Liver Fibrosis and Prognosis in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  75. EASL Machine Learning Models Accurately Interpret Liver Histology and Are Associated With Disease Progression in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  76. EASL Hepatic Transcriptomic Analysis Identifies a Mast Cell Gene Expression Signature That Correlates With Fibrosis Stage and Is Prognostic in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  77. EASL Removal of Fibrosis-Related Genes Identifies a Hepatic Gene Expression Signature That Identifies Canonical Signaling Pathways and Is Correlated With Clinical Outcomes in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  78. EASL Cotadutide Tames Metabolic Markers in Overweight/Obese With Diabetes - Mark Mascolini - (09/17/20)
     
  79. EASL THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION - (09/15/20)
     
  80. EASL Myosteatosisis strongly associated with NASH in humans and in preclinical NAFLD models - (09/15/20)
     
  81. EASL Machine learning to predict recurrence of early-stage HCC before therapy using baseline MRI - (09/15/20)
     
  82. EASL Glympse Liver Test for Noninvasive Monitoring of Combination Drug Therapy in a Rat Model of Nonalcoholic Steatohepatitis - (09/15/20)
     
  83. The Pharmacokinetics, Pharmacodynamics, and Short-term Safety of Cilofexor, a Nonsteroidal Farnesoid X Receptor Agonist, in Subjects With Hepatic Impairment - (09/15/20)
     
  84. EASL Concentration-QT Analysis of Firsocostat, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor - (09/15/20)
     
  85. EASL Improvements in the ELF Test Are Associated With Widespread Changes in the Hepatic Transcriptome in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)
     
  86. EASL Machine Learning Models Identify Novel Histologic Features Predictive of Clinical Disease Progression in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)
     
  87. EASL Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH) - (09/15/20)
     
  88. EASL Europe's largest meta-analysis on the prevalence of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and advanced fibrosis (F3-F4) - (09/15/20)
     
  89. EASL Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - (09/15/20)
     
  90. EASL Association of FIB4 score with disease progression in real -world populations diagnosed with NAFLD/NASH or at risk of NASH in US Clinical Practice - (09/04/20)
     
  91. EASL Phenome-Wide Association Study of the FIB-4 Index in a Large, Population-Based Study in the United States - (09/04/20)
     
  92. EASL The Safety and Pharmacokinetics of Fenofibrate in Patients With Advanced Fibrosis, Including Those With Nonalcoholic Steatohepatitis - (09/04/20)
     
  93. EASL Combination of an Acetyl CoA Carboxylase Inhibitor With Therapeutics That Promote Fatty-Acid Oxidation Does Not Improve Antifibrotic Efficacy in a Preclinical NASH Model - (09/04/20)
     
  94. EASL Efficacy and Safety of an Acetyl CoA Carboxylase Inhibitor Are Improved in Combination With PPAR Agonists in a Dyslipidemic Rat Model - (09/04/20)
     
  95. EASL A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH) - (09/04/20)
     
  96. EASL Liver disease progression and clinical outcomes in the Hepatic Outcomes and Survival Fatty liver Registry (HOTSURFR) Study - (09/04/20)
     
  97. EASL FXR Agonist EDP-305 Lowers ALT and Liver Fat in NASH - Mark Mascolini (08/31/20)
     
  98. EASL Nidufexor Lowers ALT and Liver Fat at 12 Weeks in NASH Patients - Mark Mascolini (08/31/20)
     
  99. EASL TVB-2640 Lowers Liver Fat, Improves Fibrosis, in Phase 2a NASH Trial - Mark Mascolini (08/31/20)
     
  100. EASL Liver and Heart Disease, Nonsolid Cancers, Lead Causes of Death With NAFLD - Mark Mascolini (08/31/20)
     
  101. EASL Safety and Efficacy of Combination Therapies Including Cilofexor/Firsocostat in Patients With Bridging Fibrosis and Cirrhosis Due to NASH: Results of the Phase 2b ATLAS Trial (08/31/20)
     
  102. EASL CCR2/5 Antagonist Plus FGF21 Analog Quell Liver Fat, Fibrosis in Mice - Mark Mascolini (08/31/20)
     
  103. EASL NASH and Visceral Fat Tied to Adipose IR Independently of BMI - Mark Mascolini (08/31/20)
     
  104. EASL Despite Evidence of Benefit in NASH, GLP1a and SGLT2i Use Low in US - Mark Mascolini (08/31/20)
     
  105. EASL More Comorbidities With NAFLD/NASH Than Hepatitis in Global Survey - Mark Mascolini (08/31/20)
     
  106. EASL Causes of Death in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Data from National Vital Statistics System (NVSS) - (08/31/20)
     
  107. EASL Multidisciplinary NAFLD Approach Yields Strong CVD Risk Gains - Mark Mascolini (08/27/20)
     
  108. EASL Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials - (08/27/20)
     
  109. EASL Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression Vs Men: A Systematic Review and Meta-analysis - (08/27/20)
     
  110. Characteristics of Liver Tests in COVID-19 Patients - (08/25/20)
     
  111. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury - (08/25/20)
     
  112. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections - (08/25/20)
     
  113. Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH) - (08/10/20)
     
  114. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection - (08/10/20)
     
  115. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis - (08/10/20)
     
  116. IAC 2020 Virtual: Is NAFLD the same disease in HIV infected patients? - (08/10/20)
     
  117. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD - (07/27/20)
     
  118. Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH - press release - (06/29/20)
     
  119. Fatty Liver in HIV: what the HIV Clinician Needs to Know - (06/19/20)
     
  120. Lean NAFLD in HIV+ 14% - Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus - (06/19/20)
     
  121. Barriers to HCV Treatment: Prior Authorization for PWID Must Be Removed, It Delays Cure & Encourages Disease Progression & Death - (06/19/20)
     
  122. Timing of hepatitis C elimination in the United States: Estimating the year each state will achieve the World Health Organization's elimination targets - (06/19/20)
     
  123. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States - PWID can be successfully cured - (06/19/20)
     
  124. HCV Testing for HIV+ - Only 50% Are Tested - (06/19/20)
     
  125. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes - (06/12/20)
     
  126. DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH - (06/05/20)
     
  127. Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort - (06/01/20)
     
  128. Fatty Liver in HIV - (05/28/20)
     
  129. New HCV Infections Tripled: 4 times Higher than in 2009 - (05/14/20)
     
  130. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD - (05/12/20)
     
  131. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/11/20)
     
  132. Non-alcoholic fatty liver disease predicts development of metabolic comorbidities in HIV-infected patients - (05/08/20)
     
  133. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/08/20)
     
  134. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/05/20)
     
  135. CROI: Hepatitis, HCV, HBV & Fatty Liver at CROI 2020 - (04/29/20)
     
  136. CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
     
  137. CROI: INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20)
     
  138. CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
     
  139. CROI: BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS (03/23/20)
     
  140. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/23/20)
     
  141. CROI: Fibrosis Progression Over 6-Fold Higher in NAFLD With vs Without HIV - Mark Mascolini (03/23/20)
     
  142. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/23/20)
     
  143. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (03/23/20)
     
  144. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/11/20)
     
  145. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/11/20)
     
  146. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease - (02/28/20)
     
  147. Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients - (02/27/20)
     
  148. Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon - (02/04/20)
     
  149. GP perceptions of liver disease; HIV & Fatty Liver/NASH NASH Diagnosis and Management in General Practice - (01/09/20)
     
  150. EACS: Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease (01/13/20)
     
  151. EACS: Hepatic steatosis in HIV+ individuals: which impact has baseline BMI and treatment with integrase inhibitors? (01/13/20)
     
  152. EACS: Evolutive NAFLD predicts frailty in people living with HIV - Mark Mascolini (01/13/20)
     
  153. Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - (01/09/20)
     
  154. Vitamin E for Fatty Liver in AASLD Guidelines - (01/09/20)
     
  155. Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients - (01/09/20)
     
  156. Obeticholic acid: towards first approval for NASH - Comment - (12/13/19)
     
  157. AASLD: Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH - (12/13/19)
     
  158. AASLD: Tropifexor (TXR), an FXR Agonist for the Treatment of NASH - Interim Results from First Two Parts of Phase 2b Study FLIGHT-FXR - (12/13/19)
     
  159. AASLD: Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/13/19)
     
  160. AASLD: SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OBETICHOLIC ACID IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS OR CIRRHOSIS - (12/03/19)
     
  161. AASLD: ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL - (12/03/19)
     
  162. AASLD: Obeticholic Acid Treatment in Patients with Non-alcoholic Steatohepatitis: A Secondary Analysis of the REGENERATE Study Across Fibrosis Stages - (12/03/19)
     
  163. Impact of Prescribed Treatment Duration on Hepatitis C Treatment Adherence: Comparison of 8- and 12-Week Treatment With Glecaprevir/Pibrentasvir - (12/12/19)
     
  164. AASLD: LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/10/19)
     
  165. AASLD: LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/09/19)
     
  166. AASLD: Higher Number of Concurrent Metabolic Co-Morbidities Is Associated with Increasingly Higher Risk of Significant Hepatic Fibrosis and Cirrhosis in Nonalcoholic Fatty Liver Disease Patients - (12/09/19)
     
  167. AASLD: MELD-score changes in relation to clinical outcome following DAAs in HCV-infected patients with cirrhosis - (12/09/19)
     
  168. AASLD: Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/09/19)
     
  169. AASLD: Ultrasound-based Controlled Attenuation Parameter (CAP) to Detect Longitudinal Changes in Liver Fat When Effect Size is Large -Experience From a Phase 2a, Dose-ranging Study Assessing MRI-Proton Density Fat Fraction (PDFF) and CAP In Parallel - (12/05/19)
     
  170. AASLD: PF-05221304 (PF'1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-Phase 2a, dose-ranging study - (12/05/19)
     
  171. AASLD: Safety and Efficacy of 10mg (high-dose) bulevirtide (Myrcludex B) in combination with PEG-IFNa or TDF in patients with chronic HBV/HDV co-infection: interim results. - (12/05/19)
     
  172. AASLD: A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (12/05/19)
     
  173. AASLD: THE IMPACT OF PRURITUS ON PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA) - (12/05/19)
     
  174. EACS: Non-Alcoholic Fatty Liver Disease is a significant predictor of cardiovascular risk in HIV-mono-infected patients (12/04/19)
     
  175. AASLD: Factors Associated with Mortality in Lean, Overweight and Obese Patients with Non-alcoholic Fatty Liver Disease - (11/25/19)
     
  176. AASLD: Machine Learning Models Accurately Interpret Liver Histology in Patients With Nonalcoholic Steatohepatitis - (11/19/19)
     
  177. AASLD: Innovative Machine Learning Tool Predicts Who Might Have Non-Alcoholic Steatohepatitis - (11/19/19)
     
  178. AASLD: Machine Learning Models Accurately Interpret Liver Histology in Patients With Nonalcoholic Steatohepatitis - (11/19/19)
     
  179. EACS: Fibrosis, Steatosis, and NAFLD Boost Odds of Frailty in HIV Group - Mark Mascolini (11/13/19)
     
  180. Tesamorelin, liver fat, and NAFLD in the setting of HIV - Comment / Tesamorelin Prevented Progression to Liver Fibrosis in NIH Study - (10/25/19)
     
  181. Aging/HIV & Senescence; NASH - (07/08/19)
     
  182. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV.......33% hepatic steatosis >/= grade 1 vs 10% controls - > grade 2 28% vs 5% controls - belly, metabolics - (06/28/19)
     
  183. 20th Intnl Wrkshp Clin Pharm: Alteration of Hepatic OATP Activity Does Not Alter the Pharmacodynamic Effect of GS-0976, a Liver-Targeted ACC Inhibitor, on De Novo Lipogenesis - (05/26/19)
     
  184. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries - (05/24/19)
     
  185. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  186. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis - (05/14/19)
     
  187. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication - (05/13/19)
     
  188. NAFLD in lipodystrophy - (05/10/19)
     
  189. EASL: THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders - (05/09/19)
     
  190. Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) - (05/08/19)
     
  191. EASL: NGM313, a Novel Activator of β-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (Liver Fat by MRI-PDFF), Inflammation (ALT, AST) and FibrogenicActivity (Pro-C3) in NAFLD Subjects - (05/08/19)
     
  192. EASL: Merck (Fatty Liver Disease/NASH) and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022 - (05/08/19)
     
  193. EASL: New Non-Invasive NASH/Fibrosis Biomarkers - A Comparative Study of Fibrosis Treatments using Aptamer-Based Quantitative Proteomics in a Model of Nonalcoholic Steatohepatitis Cirrhosis - (05/08/19)
     
  194. EASL: A Novel Approach to Funding HCV and HBV Treatment for all -Uzbekistan Pilot Project - (05/08/19)
     
  195. EASL: The short and long term impact of scaling up treatment for hepatitis B and C on disease burden - (05/08/19)
     
  196. EASL: A comparison of currently available direct acting antiviral HCV therapy in Canada - On the path to elimination - (05/08/19)
     
  197. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/08/19)
     
  198. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  199. EASL: Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  200. EASL: A Simple Algorithm Based on Electronic Medical Records to Identify NAFLD with Advanced Fibrosis in Patients with Type 2 Diabetes - (05/07/19)
     
  201. EASL: The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes - (05/07/19)
     
  202. EASL: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (05/07/19)
     
  203. EASL: The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD - (05/07/19)
     
  204. NAFLD in Lean Person EASL - Symposium: Recognising and managing the lean NAFLD patient - (05/01/19)
     
  205. EASL: Food, Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD) - (04/30/19)
     
  206. EASL: LIFESTYLE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - (04/30/19)
     
  207. EASL: The socio-economic burden of NASH in Europe and the United States: the GAIN study - (04/26/19)
     
  208. EASL: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases - (04/23/19)
     
  209. EASL: High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance - (04/23/19)
     
  210. EASL: EASL Wrap-up session: Metabolic and alcohol related liver disease, Fatty Liver/NASH - (04/23/19)
     
  211. EASL: Liver Disease in UK General Population: Fatty & Alcohol Liver Disease; Lack of Awareness: 4% aware; High Rate of Risk Factors: 89% - (04/23/19)
     
  212. FATTY LIVER in HIV+, alcohol, 50% have NAFLD, 27% Liver Fibrosis - The prevalence of liver fibrosis in HIV infected patients with abnormal liver function tests - (04/23/19)
     
  213. EASL: Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis - (04/22/19)
     
  214. EASL: A Combination of the ACC Inhibitor GS-0976 (firsocostat) and the Nonsteroidal FXR Agonist GS-9674 (cilofexor) Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients With Nonalcoholic Steatohepatitis - (04/22/19)
     
  215. EASL: APPLICATION OF GUIDELINES FOR FATTY LIVER IN TWO PROSPECTIVE COHORTS OF HIV+ PATIENTS: 32% have NAFLD; among those without NAFLD 18% with elevated ALT - (04/22/19)
     
  216. EASL: The Increasing Importance of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Human Immunodeficiency Virus (HIV) - (04/18/19)
     
  217. EASL: Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH - (04/13/19)
     
  218. EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
     
  219. The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease - Editorial - (04/10/19)
     
  220. Cirrhosis Causes Cognitive impairment, Poor Patient Outcomes - Despite HCV, SVR in the Presence of NAFLD, Alcoholic Fatty Liver Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis - (04/10/19)
     
  221. Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs .....Two thirds of HVs referred for treatment received treatment with 100% [13/13] achieving SVR12. - (04/10/19)
     
  222. Study Confirms Tesamorelin Significantly Reduces Liver Fat in HIV Patients With NAFLD - press announcement - (04/02/19)
     
  223. SHIVER: 1ST INTERNATIONAL WORKSHOP OF THE STEATOHEPATITIS IN HIV EMERGING RESEARCH (SHIVER) NETWORK - (03/01/19)
     
  224. Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - (02/27/19)
     
  225. Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (01/14/19)
     
  226. Merck Exercises Option for NGM Bio's Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes - (01/08/19)
     
  227. AASLD: Trends in Causes of Mortality in Liver Transplantation Recipients: Comparison Among NASH, ALD, and HCV Cohorts - (01/04/19)
     
  228. AASLD: Health care costs associated with NAFLD - a long-term follow up study - (01/04/19)
     
  229. AASLD: Economic Burden of Progression to Cirrhosis in Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States - (12/14/18)
     
  230. AASLD: Prevalence and Long-term Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) Among Elderly Individuals from the United States - (12/14/18)
     
  231. AASLD: Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease: The Impact of Alcohol Consumption and Metabolic Syndrome to Mortality - (12/14/18)
     
  232. AASLD: NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis(NASH) Results of a Phase 2 Multi-Center Dose Finding Study - (12/12/18)
     
  233. AASLD: NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study - (12/12/18)
     
  234. AASLD: NGM313, a Novel Once-Monthly Activator of bKlotho-FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Non- Alcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin-Resistant Patients with NAFLD - (12/12/18)
     
  235. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  236. AASLD: Validation of Fractional Synthesis Rate of Plasma Lumican as a Noninvasive Marker of Fibrogenesis in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  237. AASLD: The Incidence of Malignancies in Nonalcoholic Fatty Liver Disease - (12/11/18)
     
  238. AASLD: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Acetyl-CoA Carboxylase Inhibitor GS-0976, and Phenotypic Probe Substrates and Inhibitors - (12/11/18)
     
  239. AASLD: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (12/10/18)
     
  240. AASLD: Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis - (11/16/18)
     
  241. AASLD: Rising and Higher Healthcare Resource Utilization (HCRU) and Costs of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease of Increasing Severity - Results of a US Real-World Analysis - (11/16/18)
     
  242. AASLD: ASK1 Inhibition Reduces Progression of Liver Cirrhosis and Prevents Tumor Development in the BALB/c.Mdr2-/- Mouse Model of Biliary Fibrosis - (11/15/18)
     
  243. AASLD: Routinely Available Noninvasive Tests Discriminate Advanced Fibrosis Due to NASH in the Phase 3 STELLAR Trials of the ASK1 Inhibitor Selonsertib - (11/15/18)
     
  244. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (11/15/18)
     
  245. AASLD: The Nonsteroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2, Randomized, Placebo-Controlled Trial of Patients With NASH - (11/15/18)
     
  246. AASLD: The Nonsteroidal Farnesoid X Receptor Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis: A Phase 2, Randomized, Placebo-Controlled Trial - (11/15/18)
     
  247. AASLD: Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial - (11/15/18)
     
  248. AGE: More than 40% of HIV group has hepatic steatosis, regardless of age - Mark Mascolini (09/19/18)
     
  249. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  250. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  251. Mechanisms of NAFLD development and therapeutic strategies - (07/18/17)
     
  252. Time to step-up the fight against NAFLD - Comments from the Editors - (07/18/17)
     
  253. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database - (06/27/18)
     
  254. Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists - (06/15/18)
     
  255. EASL: The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/23/18)
     
  256. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis: A Population Pharmacokinetics and Exposure-Response Analysis - (05/22/18)
     
  257. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue, Reduces Fibrosis and PRO-C3 in a Mouse Model of Non-Alcoholic Steatohepatitis - (05/22/18)
     
  258. Evaluation of SOMAscan® as a Discovery Platform to Identify Noninvasive
    Protein Biomarkers for Diagnosis and Monitoring of NASH
    - (05/21/18)
     
  259. The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/21/18)
     
  260. EASL: ACC Inhibitor Demonstrates Potent Antifibrotic Activity In Vitro and In Vivo - (05/17/18)
     
  261. EASL: Responsiveness of Controlled Attenuation Parameter and Its Correlation With Magnetic Resonance Imaging-Proton Density Fat Fraction in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (05/15/18)
     
  262. EASL: Combination of an FXR Agonist and an ACC Inhibitor Increases Antifibrotic Efficacy in Rodent Models of NASH - (05/15/18)
     
  263. EASL: Preliminary Efficacy and Safety of Acetyl-CoA Carboxylase Inhibitor GS-0976 in Patients With Compensated Cirrhosis Due To NASH - (05/15/18)
     
  264. EASL: Accurate Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH Using a Bayesian Machine Learning Approach - (05/15/18)
     
  265. EASL: The Conundrum of Cryptogenic Liver Disease [NASH] with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options - (05/15/18)
     
  266. EASL: Novel Characterization of the Gut Microbiome in Patients With NASH and Longitudinal Changes Associated With Histologic Improvement - (05/15/18)
     
  267. EASL: Mechanism for Hypertriglyceridemia and Effect of Fibrate Coadministration During Acetyl-CoA Carboxylase Inhibitor Treatment - (05/11/18)
     
  268. EASL: Characterization of Changes in Lipoprotein Profiles of Patients With Nonalcoholic Steatohepatitis Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976 - (05/09/18)
     
  269. EASL: An Integrated Safety Analysis of Phase 2 Studies of BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis - (04/25/18)
     
  270. EASL: Low-moderate alcohol use is associated with a lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) - (04/24/18)
     
  271. EASL: Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI - (04/24/18)
     
  272. EASL: Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/24/18)
     
  273. EASL: Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): A large German claims database study - (04/23/18)
     
  274. EASL: NGM282 Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - (04/20/18)
     
  275. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/19/18)
     
  276. EASL: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (04/19/18)
     
  277. EASL: NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks - (04/19/18)
     
  278. EASL: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH) - (04/19/18)
     
  279. EASL: MGL-3196, a selective thyroid hormone receptor-beta agonist, significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study - (04/19/18)
     
  280. EASL: Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2b CENTAUR Study - (04/19/18)
     
  281. EASL: Proof-of-concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor (FXR) agonist (GS-9674) in NASH - (04/18/18)
     
  282. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/18/18)
     
  283. NASH Future Therapies at Paris Hepatitis Conference Jan 2018 - (02/05/18)
     
  284. Merck NASH - (01/30/18)
     
  285. Fatty Liver, NASH in HIV - (01/30/18)
     
  286. Long Term Outcomes: Mortality and Causes of Death in NAFLD - (01/30/18)
     
  287. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus - (01/08/18)
     
  288. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention - (01/08/18)
     
  289. Fatty liver disease: turning the tide - (01/08/18)
     
  290. Nonalcoholic fatty liver disease.....liver enzymes-ALT/HIV/diet, exercise, metabolic syndrome, waist circumfrance, dysfunctional adipose tissue, diabetes, screening - (01/08/18)
     
  291. Fatty Liver, NASH - Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis - (01/02/17)
     
  292. Pharmacotherapy for NASH: Current and emerging - (01/02/17)
     
  293. Determinants of fibrosis progression and regression in NASH - (01/02/17)
     
  294. NAFLD: The evolving landscape - Editorial - (01/02/17)
     
  295. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  296. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  297. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  298. NAFLD AASLD Guidelines - The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases - (12/22/17)
     
  299. NAFLD and cancer: More cause for concern? - (12/21/17)
     
  300. Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD) / HIV & the Liver, Fatty Liver/NALFD - (12/20/17)
     
  301. The Global Epidemiology of Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis - (12/19/17)
     
  302. Burden of Illness Economic Model for Patients with Non-alcoholic Steatohepatitis (NASH) in the United States - (12/19/17)
     
  303. AASLD: Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease - (12/15/17)
     
  304. PPIs Increase NASH Risk - Microbiome & Fatty Liver: gut barrier dysfunction reported by speaker, leads to increased microbes into gut going to liver, increasing inflammation, and fatty liver - (12/11/17)
     
  305. HEP DART presentations 3 -7 Dec 2017 - (12/12/17)
     
  306. HEP-DART presentations 3 Dec - 7, 2017 - (12/11/17)
     
  307. NASH Globally - Pathways to combination therapies, biomarkers and outcomes - (12/11/17)
     
  308. Unmet needs in understanding pathogenesis and management of NAFLD and NASH - (12/11/17)
     
  309. AASLD: Cardiovascular risk in NAFLD- not an equal opportunity: implications for women's health - (11/29/17)
     
  310. Cirrhosis Predicts Bad Outcomes in NASH - (07/08/17)
     
  311. Cutting out the liver fat [NASH - better animal models needed] - Editorial - (07/08/17)
     
  312. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  313. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  314. AASLD: Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts early NASH and disease activity - (11/29/17)
     
  315. AASLD: NAFLD Debrief AASLD 2017 - (11/29/17)
     
  316. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/29/17)
     
  317. AASLD: 4D Dynamic FDG-PET correlates with hepatic inflammation and steatosis in patients with non-alcoholic steatohepatitis - (11/29/17)
     
  318. AASLD: Multi-Biomarker Validation of MRI-PDFF- and MRE-Derived Treatment Response with BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  319. AASLD: Baseline Serum Pro-C3 Predicts Response to BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  320. AASLD: Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 "FIB-C3 Score" for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort - (11/20/17)
     
  321. AASLD: Prevalence and Clinical Characteristics of Nonalcoholic Fatty Liver Disease in Lean Subjects in Comparison with Overweight or Obese Individuals: A cross-sectional study - (11/20/17)
     
  322. AASLD: Advanced machine learning techniques to identify a panel of biomarkers that identify non-alcoholic steatohepatitis - (11/20/17)
     
  323. AASLD: Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test - (11/20/17)
     
  324. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/20/17)
     
  325. AASLD: CM-101 a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model - (11/20/17)
     
  326. AASLD: Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis - (11/20/17)
     
  327. AASLD: The Long-Term Clinical Course of Histologically Advanced NAFLD. Impact of Fibrosis Severity on Major Clinical Outcomes. - An International and Multicenter Cohort Study - (11/17/17)
     
  328. AASLD: Natural History of Nonalcoholic Fatty Liver Disease in Children - (11/17/17)
     
  329. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (10/28/17)
     
  330. AASLD: BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study - (10/26/17)
     
  331. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  332. AASLD: Identification of Circulating MicroRNAs Altered by an Apoptosis Signal-Regulating Kinase 1 Inhibitor in a Fast-food Diet NAFLD Mouse Model - (11/14/17)
     
  333. AASLD: Plasma Metabolites for de Novo Lipogenesis and Pharmacodynamic Activity of Acetyl-CoA Carboxylase Inhibitor GS-0976 - (11/14/17)
     
  334. AASLD: Variability in Measurement of Hepatic Venous Pressure Gradient in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis: Results From a Randomized, Controlled Trial - (11/14/17)
     
  335. AASLD: Hepatic Venous Pressure Gradient Predicts Clinical Disease Progression in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (11/14/17)
     
  336. AASLD: Hepatic de Novo Lipogenesis Is Elevated in Patients With NASH Across the Spectrum of Disease Severity - (11/14/17)
     
  337. AASLD: Reductions in Hepatic Proton Density Fat Fraction Predict Histologic Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  338. AASLD: Reductions in Liver Stiffness by Magnetic Resonance Elastography Predict Fibrosis Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  339. AASLD: Serum Pro-C3 Is Associated With Hepatic Steatosis and Fibrosis, and Responsive to Changes in Steatosis in Patients With NASH - (11/13/17)
     
  340. AASLD: Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/13/17)
     
  341. AASLD: Prospective Validation of Hepatic Collagen Content for the Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH - (11/13/17)
     
  342. AASLD: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) - (11/13/17)
     
  343. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (11/13/17)
     
  344. AASLD: Combination of ASK1 and ACC Inhibitors Increases Efficacy in Rodent Models of NASH - (11/13/17)
     
  345. AASLD: Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamic Effects on de Novo Lipogenesis of the Acetyl-CoA Carboxylase Inhibitor GS-0976 in Healthy Volunteers - (11/13/17)
     
  346. AASLD: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function, and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH - (11/13/17)
     
  347. AASLD: norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study - (11/13/17)
     
  348. AASLD: Racial and Ethnic Disparities in Non-Alcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Meta-Analysis - (11/13/17)
     
  349. AASLD: Performance of liver stiffness by FibroScan in a Large Prospective Multicenter UK Study: Applicability, reliability, diagnostic performance and influence of the probe type and of steatosis on the liver stiffness measurement - (11/13/17)
     
  350. NASH: Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study - New trends on obesity and NAFLD in Asia / Lean-NASH - (10/03/17)
     
  351. Treatment of NAFLD with diet, physical activity and exercise - (09/26/17)
     
  352. EASL: Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/08/17)
     
  353. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter - (09/05/17)
     
  354. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD - (09/05/17)
     
  355. IAS: Fatty Liver in HIV+ at IAS - (08/05/17)
     
  356. Current and Future Therapeutic Approaches to NAFLD/NASH - (08/05/17)
     
  357. IAS: Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17)
     
  358. Bristol-Myers NASH drug hits primary endpoint in phase 2 - (07/22/17)
     
  359. Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial - (07/22/17)
     
  360. EASL: A NEW NON-INVASIVE DIAGNOSTIC SCORE TO MONITOR CHANGE IN DISEASE ACTIVITY AND PREDICT FIBROSIS EVOLUTION IN PATIENT WITH NASH - (07/17/17)
     
  361. EASL: Prospective Prevalence Study of Adult NAFLD/NASH Utilizing Multi-Modality Imaging Compared with Liver Biopsy - (07/17/17)
     
  362. EASL: Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies - (07/17/17)
     
  363. EASL: Simple non-invasive fibrosis scores identify patients with NAFLD who progress to advanced fibrosis/cirrhosis: evidence from a large cohort of patients with sequential liver biopsies. - (07/17/17)
     
  364. EASL: DNA Methylation Signatures in Blood Show Accelerated Epigenetic Aging in Patients with Nonalcoholic Steatohepatitis Compared to Healthy Controls - (07/07/17)
     
  365. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease - (07/07/17)
     
  366. EASL: Changes in Fibrosis, But Not the NAFLD Activity Score, Are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (07/06/17)
     
  367. EASL: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial - (07/05/17)
     
  368. EASL: INT 747 (obeticholic acid) fails to achieve goals in Japanese study for non-alcoholic steatohepatitis (NASH)- Intercept Pharma + Sumitomo - (07/05/17)
     
  369. EASL: Starting the battle to control non-alcoholic steatohepatitis [OCA FLINT Study] - Comment - (07/05/17)
     
  370. EASL: Nonalcoholic Steatohepatitis Drug Pipeline Overview - (07/05/17)
     
  371. EASL: Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis - (07/05/17)
     
  372. EASL: Elafibranor - (GFT505) NASH Treatment - GOLDEN 505 Study & Commentary - (07/05/17)
     
  373. EASL: Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes - (07/05/17)
     
  374. EASL: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Farnesoid X Receptor Agonist GS-9674, and Phenotypic Probe Substrates and Inhibitors/Inducers - (07/03/17)
     
  375. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  376. EASL: Emerging Treatments for ASH & NASH - Rohit Loomba, MD / AASLD 2016 - (07/03/17)
     
  377. EASL: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Reduces Hepatic Steatosis and Liver Injury in a Murine Model of NASH - (07/03/17)
     
  378. EASL: Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multicenter Nonalcoholic Steatohepatitis Clinical Trial - (07/03/17)
     
  379. EASL: Apoptosis Signal-Regulating Kinase 1 Inhibition Reduces Liver Fibrosis and Apoptosis in an NLRP3 Mutant Model of NASH - (07/03/17)
     
  380. EASL: Impact of Weight Reduction on Serum Markers and Liver Histology Including Progression to Cirrhosis in Patients With Nonalcoholic Steatohepatitis and Bridging Fibrosis - (07/03/17)
     
  381. EASL: Impact of Modest Weight Reduction on Liver Histology, Portal Pressure, and Clinical Events in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (07/03/17)
     
  382. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  383. Fatty Liver in HIV+ / HIV Research Politics, Aging - Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy - (07/03/17)
     
  384. IWCADRH: Clinical Implications of Nonalcoholic Fatty Liver Disease in Patients with HIV Infection - (06/23/17)